Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
31
October
2025
Clearmind Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application
Read More
30
October
2025
Clearmind Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Read More
28
October
2025
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
Read More
27
October
2025
Clearmind Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Read More
21
October
2025
Clearmind Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Read More
20
October
2025
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
Read More
25
September
2025
Clearmind Medicine Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Read More
19
September
2025
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Read More
7
August
2025
Clearmind Announces International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Read More
5
August
2025
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
Read More
30
July
2025
Clearmind Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Read More
23
July
2025
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Read More
15
July
2025
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Read More
3
July
2025
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for AUD at Tel Aviv Sourasky Medical Centre
Read More
30
June
2025
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for AUD
Read More
Next
